Related references
Note: Only part of the references are listed.Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
D. Santini et al.
CURRENT CANCER DRUG TARGETS (2010)
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
Luigi Dolcetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model
Penelope D. Ottewell et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer
Kishan J. Pandya et al.
LUNG CANCER (2010)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Francesco Colotta et al.
CARCINOGENESIS (2009)
Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials
M. Gnant
CURRENT CANCER DRUG TARGETS (2009)
Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development
Verena Greifenberg et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Role of macrophages in tumour progression
K. S. Siveen et al.
IMMUNOLOGY LETTERS (2009)
Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells
Yu-Jen Chen et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2009)
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi et al.
INTERNATIONAL IMMUNOLOGY (2009)
Chorionic gonadotropin alleviates thioglycollate-induced peritonitis by affecting macrophage function
Hui Wan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Zoledronic acid is effective against experimental malignant pleural effusion
Georgios T. Stathopoulos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up
I. J. Diel et al.
ANNALS OF ONCOLOGY (2008)
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages
Panagiotis Tsagozis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis
Sabina Sangaletti et al.
CANCER RESEARCH (2008)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages
Paola Allavena et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance
Paola Allavena et al.
IMMUNOLOGICAL REVIEWS (2008)
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics
Naoki Umemura et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
Nathan R. Miselis et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Nitric oxide, apoptosis and macrophage polarization during tumor progression
Andreas Weigert et al.
NITRIC OXIDE-BIOLOGY AND CHEMISTRY (2008)
Macrophage polarization in tumour progression
Antonio Sica et al.
SEMINARS IN CANCER BIOLOGY (2008)
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
Cecilia Melani et al.
CANCER RESEARCH (2007)
Chorionic gonadotropin can enhance innate immunity by stimulating macrophage function
Hui Wan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation
Michele Caraglia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Clodronate-liposome-mediated depletion of tumour-associated macrophages:: a new and highly effective antiangiogenic therapy approach
S. M. Zeisberger et al.
BRITISH JOURNAL OF CANCER (2006)
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. P. J. J. Hegmans et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
A Sica et al.
EUROPEAN JOURNAL OF CANCER (2006)
Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
J Condeelis et al.
CELL (2006)
Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro
S Rössner et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro
Y Ohtsuka et al.
BLOOD (2005)
Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
K Sato et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Regulation of immune responses by L- arginine metabolism
V Bronte et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Recent developments in bisphosphonates for patients with metastatic breast cancer
MC Gainford et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Anti-tumour activity of zoledronic acid
P Clezardin
CANCER TREATMENT REVIEWS (2005)
Differential inhibition of invasion and proliferation by bisphosphonates: Anti-metastatic potential of Zoledronic acid in prostate cancer
R Montague et al.
EUROPEAN UROLOGY (2004)
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
E Giraudo et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model
T Hiraga et al.
CLINICAL CANCER RESEARCH (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini et al.
ANNALS OF ONCOLOGY (2003)
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival
O Fromigue et al.
BRITISH JOURNAL OF CANCER (2003)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Immature myeloid cells and cancer-associated immune suppression
S Kusmartsev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Tumor-induced immune dysfunctions caused by myeloid suppressor cells
V Bronte et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen
F Miyagawa et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
